



Africa Pharma Conference 2019 (June 4th – 5th)

Programme

Schedule	Synopsis of session and talking points
<p>9:00 Opening Ceremony</p> <p>Welcome Remarks: Dr. Ibrahim Assane Mayaki, CEO, African Union Development Agency-NEPAD</p> <p>High Level Statements:</p> <ul style="list-style-type: none">• Mr Emmanuel Mujuru – Chair, Federation of African Pharmaceutical Manufacturers Associations (FAPMA)• Mariângela Simao – ADG, WHO - Access to Medicines, Vaccines and Pharmaceuticals Cluster• Dr. Manuel Nso Obiang ADA - CEO, OCEAC• Mr. Li Young – DG, UNIDO• Adv. Bience Gawanas – USG Special Adviser, UN-SAA• H.E Mrs. Amira Mohamed El- Fadil – Commissioner, AUC Department of Social Affairs• Official Opening – Mr. Lionel October– DG of Department of Trade and Industry of South Africa	<p>This session addresses the broad vision for the conference. It is followed by High Level Statements from principal stakeholders in Africa’s quest to improve universal access to quality assured affordable essential medicines and catalyzing of local production in Africa.</p>
<p>10:00-10:15am. Photographs</p>	
<p>10.15 – 11.30 hrs. High Level Panel Discussion</p>	<p>This high-level session is aimed at discussing the overall continental leadership vision for local production; articulate the issues of political</p>





<p>Chair: Dr. Ademola Olajide – Representative, UNFPA</p> <p>Panelists:</p> <ul style="list-style-type: none"> • Dr Clet Niyikiza – President/CEO, LEAF Pharmaceuticals • Adv. Bience Gawanas – USG Special Adviser, UN-SAA • Mariângela Simao – ADG WHO, Access to Medicines, Vaccines and Pharmaceuticals Cluster • Mr. Kofi Adomakoh - Director, Project and Asset Finance, Afrexim Bank • Mr. Tenu Avafia- UNDP • Dr. Malebona Precious Matsoso, Director General, Department of Health, South Africa 	<p>will, national vision and strategies. It will examine the issue of policy coherence and coordination within and between national governments for seamless execution. The session will describe the key steps necessary to champion the growth on an infant local production industry on the African continent.</p> <p>Talking points include:</p> <ul style="list-style-type: none"> • Discussion on Political Will, National Vision and Strategies • What a coherent policy framework looks like – Governmental coordination for seamless execution • National Champions to drive Infant industry development • Commitment of funding and creating the right incentive framework
<p>Tea break 11:30-11:45am</p>	
<p>11.45 – 13.15 hrs: Strategic continental initiatives</p> <p>Chair – Dr. Clémence Aissatou Bare Habi – Director UNAIDS liaison office to the AU and UNECA</p> <p>Presentations:</p> <ul style="list-style-type: none"> • Africa Medicines Regulatory Harmonization (AMRH) – Mrs. Margareth Ndomondo-Sigonda - Head of Health Programs, AUDA-NEPAD • Africa Continental Free Trade Area (AfCFTA) – Mr. Prudence Sebahizi - Coordinator CFTA AUC (Department of Trade and Industry) 	<p>Synopsis of session and talking points</p> <p>This session will provide an overview of relevant continental initiatives of the African Union and its agencies, which can be explored for critical synergies to advance the agenda of access to medicines, especially as it relates to local production. Information will be provided on the status of implementation, results delivered till date, challenges and processes/interventions necessary to deliver on the overall strategic objectives.</p>



<ul style="list-style-type: none">• Accelerating Industry Development for Africa (AIDA) Frank Dixon Mugenyi –Senior Industry Advisor Office of the Commissioner (Department of Trade and Industry AUC• Accelerating Excellence in Science in Africa (AESAs) – Prof. Nelson Torto – Executive Director, African Academy of Sciences (AAS)• Tackling Infections to Benefit Africa (TIBA) - Prof Francisca Mutapi – Deputy Director TIBA ----remove all the words before this.	
<p>11.45 – 13.15 hrs – Creating the right financial instruments for LPP, Financing initiatives: Origination, Structuring and Execution; including boosting intra-African trade</p> <p>Presentations:</p> <ul style="list-style-type: none">• The Opportunity for local pharmaceutical manufacturing in sub-Saharan Africa – Tania Holt, Partner, Mckinsey <p>Chair - Mr. Kofi Adomakoh Director, Project and Asset Finance – Afrexim Bank</p> <p>Panellists:</p> <ul style="list-style-type: none">• Babatunde Omilola – Head of Division – Public Health, Social Protection and Nutrition Division, African Development Bank (AFDB)• Dr. Njeri Mwaura, Senior Health Specialist, International Finance Corporation (IFC)	<p>Synopsis of session and talking points</p> <p>The session will start by a brief presentation by Tania Holt, titled: The Opportunity for local pharmaceutical manufacturing in sub-Saharan Africa</p> <p>This session will contextualize the realities that confront local production of pharmaceuticals in Africa (LPP) and will provide strategic insights into the opportunities for local production. Given the fact that structuring of financial services and products have not always met the specific requirements of the industry on the continent, the session will highlight some opportunities to access to the financing necessary to support the initiative.</p>



<ul style="list-style-type: none">• Dr. Tania Sitoie, National Director, for Pharmaceuticals, Ministry of Health, Government of Mozambique.• Tania Holt, Partner, Mckinsey	
13.15 – 14.15 – Lunch Break	
<p>14.15 – 15.30 hrs – The next Frontier for Public Health Medicines Market – rethinking priorities for improved access to quality-assured medicines for Universal Access</p> <p>Chair – Mr. Olakunle Olaniyi-Edwards – Executive Director, DFS Africa</p> <p>Panelists:</p> <ul style="list-style-type: none">• Dr Jayasree K. Iyer – CEO, Access to Medicines Foundation• Dr S. Nwaka – Executive Director, ANDI• Mr Stavros Nicolaou –Senior Executive - Strategic Trade Dev, Strategic Trade, Aspen Pharmacare• Kwasi Boateng – Director, United States Pharmacopeia Ghana• Mr Emmanuel Mujuru – Chair of Board, FAPMA• Dr Ifeanyi Okoye OFR, mni – CEO Juhel Nigeria Limited	<p>Synopsis of session and talking points</p> <p>With nearly 2 billion people still lacking access to essential medical products and with global pharmaceutical markets becoming less able to respond to the needs of low- and middle-income countries, there is increasing recognition of the importance of developing a high-quality pharmaceutical manufacturing base closer to the patients in need. In 2008, the World Health Assembly adopted the Global Strategy and Plan of Action for Public Health, Innovation and Intellectual Property,” which identified investment in local production of pharmaceuticals as a key area.</p> <p>Local production of pharmaceuticals confers numerous public health and economic benefits. A strong local pharmaceutical manufacturing base can better respond to demand and limits the risk of supply interruptions. A manufacturing base which is closer to the patient simplifies and shortens the supply chain, facilitating quality assurance.</p> <p>The discussion will include a brief introductory presentation from two authors of the thought leadership paper, Dr. Skhumbuzo Ngozwana , President & Chief Executive Officer of Kiara Health and international</p>



	<p>expert on the African Pharmaceutical industry (tbc) and Mr. Kwasi Boateng, Country Director for the USAID funded and USP implemented ‘Promoting the Quality of Medicines Program’, which provides direct technical assistance to pharmaceutical manufacturers globally towards the objective of increasing access to essential public health medicines. The presentation will be followed by a professionally-moderated session to include high level representatives from government, industry and development agencies. Representatives will be asked to share their perspective on key challenges and enablers of local pharmaceutical production.</p>
<p>Tea break 15:30 -15:45am</p>	
<p>15.45 – 17.00 hrs - Health and Pharmaceutical Financing; Blended Finance, Scale Readiness for Healthcare companies, Public Private Partnerships and Transaction Structuring</p> <p>Chair: – Mr. Bankole Eniola – Executive Director, DFS Africa</p> <p>Panellists:</p> <ul style="list-style-type: none"> • Mr. Sinhue Noronha – CEO, Africure Pharmaceuticals • Mr. Ade Adebajo – Head of Sub-Saharan Africa, UBS • Dr Amit Thakker – Africa Health Business 	<p>Synopsis of session and talking points</p> <p>Governments across Africa do not have the resources to solve the most pressing health challenges across the continent. There is a need to find new funding mechanisms to achieve improved healthcare on the continent and attain Agenda 2063 and the Sustainable Development Goals (SDGs). This session has become a priority because it will focus on funding models that are scalable and can be leveraged across healthcare and pharmaceutical production across the continent.</p> <p>The session would explore how structured finance; blended finance and other innovative forms of financing structures can be used to fight</p>



	Non-Communicable Diseases and Neglected tropical diseases (NTDs) in Africa.
<p>15.45 – 17.00 hrs - Developing LPP – what is the evidence from around the world successful in promoting sustainable local production</p> <p>Chair – Dr Skhumbuzo Ngozwana – Kiara Health</p> <p>Presenters:</p> <ul style="list-style-type: none">• Leveraging government Procurement as a financial asset for local companies• Developing LPP, evidence from medicines patent pool around the world - Sandra Nobre – Medicines Patent Pool• Voluntary Licenses and Technology Transfer from a local African company to global leader; the case of Aspen - Mr, Stavros Nicolaou – ASPEN• IFPMA and Technology Transfer to Africa based manufacturers – Greg Perry <p>Panellists:</p> <ul style="list-style-type: none">• Sandra Nobre – Medicines Patent Pool• Mr, Stavros Nicolaou – ASPEN• Greg Perry – IFPMA	<p>Synopsis of session and talking points</p> <p>There are sections of the developing world and emerging economies have been successful in promoting sustainable local production of pharmaceutical products. This session seeks to highlight these concrete experiences as it relates to the continent and tease out lessons learned that can be adapted to the African realities. Recommendations, which will contribute, to the development and implementation of policy action and programmes will also be proposed.</p>



Remove all G Banda	
--------------------	--



Day Two	
Schedule	Synopsis of session and talking points
<p>8.30 – 10.00 hrs – BVGH Session</p> <p>Chair – BVGH</p> <p>Presentations:</p> <ul style="list-style-type: none"> • Takeda’s AAI cancer clinical trial fellowship program and cancer capacity building partnership with Moi Teaching & Referral Hospital (Eldoret, Kenya). - Dr. Chris Reddick, Vice President, Global Patient & Scientific Affairs; Takeda Pharmaceutical Co., Ltd. • Pfizer’s commitment to accelerating access to cancer medicines through innovative access agreements. - Mr. Muhammad Abdulkarim, Health & Value Lead, sub-Saharan Africa; Pfizer • Johnson & Johnson’s internal and external global public health R&D projects. Building R&D capacity in low- and middle-income countries through training opportunities at Johnson & Johnson. - Dr. Fred Tonelli, Head, External Innovation, Global Public Health R&D; Janssen, Pharmaceutical Companies of Johnson and Johnson 	<p>Synopsis of session and talking points</p> <p>The moderator will open the session by describing opportunities for pharmaceutical companies to improve Africa’s health and research landscape, and will introduce BVGH’s African Access Initiative (AAI) – a public-private partnership focused on addressing Africa’s cancer crisis – as one such opportunity.</p> <p>The panellists – representing pharmaceutical companies with health-related programs in Africa – will describe their companies’ programs on the continent and discuss how their customized programs can be scaled up and implemented in other locations across Africa.</p> <p>Companies represented in this session are: Takeda, Pfizer and Johnson and Johnson</p>



<p>Panellists:</p> <ul style="list-style-type: none">• Dr. Chris Reddick, Vice President, Global Patient & Scientific Affairs; Takeda Pharmaceutical Co., Ltd.• Mr. Muhammad Abdulkarim, Health & Value Lead, sub-Saharan Africa; Pfizer• Dr. Fred Tonelli, Head, External Innovation, Global Public Health R&D; Janssen, Pharmaceutical Companies of Johnson and Johnson	
<p>8.30 – 10.00 hrs - Research and Development; Harnessing the Diaspora Capacity</p> <p>Chair – Olukayode Afolabi, Executive Director, DFS Africa</p> <p>Presentations:</p> <ul style="list-style-type: none">• Leveraging Africa based research competencies - Dr. Solomon Nwaka, Executive Director for ANDI• An Africa developed blockbuster on the horizon? - Victor Moyo, Senior Vice President L.E.A.F Pharmaceuticals• Policy incentives to attract Diaspora investment and develop local talent - Dr. Clet Niyikiza - Founder of LEAF Pharmaceuticals	<p>Synopsis of session and talking points</p> <p>Knowledge management and innovation is critical to leap frog access to medicines and local production on the continent. Leveraging the capacities and experience of the African diaspora will be indispensable in aiding Local Pharmaceutical Production (LPP). This session will highlight insights gained in efforts to strengthen Research and Development as well as innovation on the continent through leveraging the tremendous human resource potential within the Africa Diaspora.</p>



<ul style="list-style-type: none">• Harnessing Diaspora scientific talent - T Gumbo, MD, Director Praedicare Labs• Leveraging advance and innovative technologies in healthcare in Africa - Sam Awotunde <p>Remove bullet point 3 -- TIBA</p> <p>Panellists:</p> <ul style="list-style-type: none">• Victor Moyo, Senior Vice President L.E.A.F Pharmaceuticals• Prof Francisca Mutapi, NIHR Global Health Research Unit;• Dr. Clet Niyikiza - Founder of LEAF Pharmaceuticals• Dr. Solomon Nwaka, Executive Director for ANDI• T Gumbo, MD, Director Praedicare Labs• Sam Awotunde	
<p>10:00 - 10.15 hrs – tea break</p>	
<p>10.15 – 11.30 hrs An Enabling Business Environment for Sustainable Quality Local Production to Improve Access</p> <p>Chair: Dr. Ossy Muganga Julius Kasilo, Technical Officer, WHO Regional Office for Africa</p> <p>Presentations:</p> <ul style="list-style-type: none">• An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production - Dr. Jicui Dong, Programme Manager, WHO-HQ	<p>Synopsis:</p> <p>Access to medical products is a pillar towards universal health coverage. Many countries view local production as a strategy to improve access of quality-assured, safe and affordable medical products. Sustainable local production of quality-assured medical products is complex and its success is dependent on cross-cutting factors working in concert. This session will explore various factors for sustainable quality local production to improve access: an enabling business environment; a collaborative approach towards local production; prequalification as a catalyst for quality local production and factors for success; the challenges and opportunities in</p>



<ul style="list-style-type: none">• Prequalification as a Catalyst for Quality Local Production and factors for success - Mr. Deuseddit Mubangizi, Coordinator, WHO-HQ• Technology Transfer and Local Production of Pharmaceuticals in Africa: Challenges and Opportunities - Dr. Ossy Muganga Julius Kasilo, Technical Officer, WHO-AFRO• Integrating a Priority for Quality Products into Procurement and Supply Chain Operations - Ms Lisa Hedman, Technical Officer, WHO-HQ <p>Panellists:</p> <ul style="list-style-type: none">• Dr. Jicui Dong, Programme Manager, WHO-HQ• Mr. Deuseddit Mubangizi, Coordinator, WHO-HQ• Dr. Ossy Muganga Julius Kasilo, Technical Officer, WHO-AFRO• Ms Lisa Hedman, Technical Officer, WHO-HQ	<p>technology transfer in Africa; and leveraging systems for quality medical products in the supply chain.</p>
<p>11.30 – 12.45 hrs - API Production in Africa – from dream to reality</p> <p>Chair – Dr. Skhumbuzo Ngozwana</p> <p>Presentations:</p> <ul style="list-style-type: none">• The need for vaccine manufacturing in Africa – Dr Morena Makhoana – CEO, Biovac• Local Vaccine Manufacturing – Mwai Ngibuini – Head, Sub-Saharan Africa for the Life Science division at Merck KGaA• APIs Manufacturing in collaboration with the Gates Foundation - Perrer N. Tosso, Ph.D. Global Innovation Manager, Medicines for All Institute	<p>Synopsis of session and talking points</p> <p>Capacity to produce active pharmaceutical ingredient (API) on the continent will remain critical to firmly establishing sustainable local production. This requires a process that should lead to efficient, reproducible, economical and safe, as well as environmentally friendly synthesis of API, which is can present a formidable challenge. This session will share concrete experience of the production API and related molecules such as vaccines on the continent, explore efforts to scale up and sustain such initiatives.</p>



<p>Panellists:</p> <ul style="list-style-type: none"> • Dr Morena Makhoana – CEO, Biovac • Mwai Ngibuini – Head, Sub-Saharan Africa for the Life Science division at Merck KGaA • Prof Joe Fortunak • Perrer N. Tosso, Ph.D. Global Innovation Manager, Medicines for All Institute 	
<p>11.30 – 12.45 hrs - Prioritized Essential Medicines and Services: Building Resilient Systems that leaves no one behind</p> <p>Chair – Dr. Tania Sitoie – National Director, for Pharmaceuticals, Ministry of Health, Government of Mozambique.</p> <p>Presentation Strengthening health systems across 4 African countries (with more to be added) across pharmacovigilance, legal environment, health technology assessments, procurement and supply chain - Tenu Avafia – UNDP</p> <p>Panellists:</p> <ul style="list-style-type: none"> • Dr Githinji Githahi, Chief Executive, AMREF Health Africa • Dr Jayasree K Iyer, Executive Director, Access to Medicine Foundation • Jude Nwokike, Senior Director of Promoting the Quality of Medicines Program, U.S. • Dr Ifeanyi Okoye OFR, mni – CEO Juhel Nigeria Limited • Tenu Avafia – UNDP 	<p>Synopsis of session and talking points</p> <p>African governments joined the global community in Astana, Kazakhstan, to celebrate 40 years of the Alma Ata Declaration on Primary Health Care and embraced Astana Declaration highlighting the indivisible linkages between investing in resilient and accountable health care system to achieving national and regional health goals, and in particular Universal Health Coverage. Although significant progress has been made much more needs to be done to garner political and legislative support towards policies, frameworks and financing models that assure that populations, especially the poor and marginalized, have access to country driven essential health services and health systems support without financial risks or being pushed into poverty. This session draws from the priority policy actions and messages of the Astana Declaration, and the complementary civil society statements to contextualize them to the continent and articulate strategic policy steps necessary to deliver on the commitments.</p>



•	
12:45– 13.45 hrs Lunch break	
<p>13.45 - 15.00hrs - Replicating and scale up of good practices, successful approaches, methodologies and interventions for universal access/local production;</p> <p>Chair – Dr Paul Lartey</p> <p>Presentations:</p> <ul style="list-style-type: none"> • UNIDO GMP Roadmap and Lean Manufacturing: The Real-World Experience – Alastair West, UNIDO; • Exploring a cost-saving approach to tumour diagnosis in Africa – Dr Sunkanmi Kola-Daisi; <p>Panellists:</p> <ul style="list-style-type: none"> • Alastair West, UNIDO • Dr Sunkanmi Kola-Daisi; 	<p>Synopsis of session and talking points</p> <p>There have been successful interventions that address some of the challenges confronting local production in African Union Member states. The results from these interventions indeed provide an opportunity to take the initiatives to scale and strengthen various components of the process to enhance local production. This session seeks to unpack these initiatives and programmes with the aim of highlighting practical steps that will take them to scale in relevant member states.</p>
<p>13.45 - 15.00hrs - Access to quality condoms (Male and Female) and other RH Medicines in Africa</p> <p>Chair – Minister of health</p> <p>Panellists:</p> <ul style="list-style-type: none"> • Dr. Ademola Olajide, Representative, UNFPA 	<p>Synopsis of session and talking points</p> <p>With Africa’s population explosion and disease burden, particularly HIV/AIDS and STIs, it is important to increase access to safe and effective reproductive health medicines and contraceptives, especially male and female condoms, which provide triple protection against unwanted pregnancies, HIV and STIs. To achieve this, it is important to address</p>



<ul style="list-style-type: none">• Ms. Bida Deperthes - Senior Technical Advisor at UNFPA• Mr. Johnpaul Omollo - Policy Advocacy Research and Development, PATH	<p>weak regulatory mechanisms and bottlenecks that limit local production and implementation of regional frameworks and agreements.</p> <p>This session will highlight policy and programme action needed to improve universal access to quality RH commodities including condoms to the last mile and catalyse local production in Africa by harnessing high-level political commitment to implementation of the various laws, strategies and frameworks of the African Union Commission</p> <p>Session Objectives;</p> <ul style="list-style-type: none">• Examine the evidence of access to RH products including condoms, existing constraints and how to overcome them, opportunities and propose a number of concrete steps that can be implemented by governments and counter parts;• Discuss a broad range of related issues including those of harmonization of regulatory protocols, production, quality control, distribution, testing and diagnosis and health care capacity development, as well as incentives that can boost local production on the African continent;• Discuss the on the opportunities of strengthening the supply chain management system in Africa and the cross-border supply chain,• Discuss the role of government, private sector, development partners in improving access to RH commodities in including
---	--



	<p>condoms in moving the African Union (AU) model law on Medical Products Regulations forward;</p> <ul style="list-style-type: none"> • Articulate a set of recommended actions;
<p>15.00 - 15.15 hrs Tea Break</p>	
<p>15:15 - 16.30hrs – Policy coherence and access to essential medicines/local production</p> <p>Chair – Minister of health</p> <p>Presentations:</p> <ul style="list-style-type: none"> • Multi-sectoral policy gaps and local production – Tenu Avafia – UNDP • Policy incentives to catalyze quick wins – Dr Skhumbuzo Ngozwana • Leveraging international development support to boost local production – Global Fund representative • Mr. Akthem Fourati – Chief of Medicines and Nutrition Centre, UNICEF <p>Panellists:</p> <ul style="list-style-type: none"> • TenU Avafia – UNDP • Dr Skhumbuzo Ngozwana – Kiara Health • Mr. Akthem Fourati – UNICEF 	<p>Synopsis of session and talking points</p> <p>This session will delve into details of what is required to ensure coherence in policies that drive access to essential medicines and local production in Africa.</p> <p>The session will focus three issues:</p> <ul style="list-style-type: none"> • How multi-sectoral policy gaps affecting local production can be mitigated. • How to advocate and implement the right policy incentives that will be used to catalyze local production of Pharma products in Africa. • How to leverage international development support to boost local production in Africa.
<p>17:00 hrs – Closing Ceremony</p>	



Presentation Outcomes of Conference - Chair Federation of African Pharmaceutical Manufacturers (FAPMA)

Statements

- **Prof. Aggrey Ambali** – Head, Industrialisation, Science, Technology & Innovation, African Union Development Agency-NEPAD.
- **H.E Mrs Amira Mohamed El- Fadil** - Commissioner for Social Affairs Chair, Permanent Representatives Committee, AUC.